Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

The Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Biomarkers of Aging in Older Overweight/Obese Adults With Insulin Resistance

Authors not listed

The University of Texas Health Science Center at San Antonio · 2023

Abstract

Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, semaglutide has on people who take the drug and the drug's effect on physical function, body composition, and aging.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-03 MST

Cite this

APA
Anonymous. (2023). The Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Biomarkers of Aging in Older Overweight/Obese Adults With Insulin Resistance. <em>The University of Texas Health Science Center at San Antonio</em>. https://clinicaltrials.gov/study/NCT05786521
Vancouver
Anonymous. The Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Biomarkers of Aging in Older Overweight/Obese Adults With Insulin Resistance. The University of Texas Health Science Center at San Antonio. 2023.
BibTeX
@misc{anon2023TheEff, title = {The Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Biomarkers of Aging in Older Overweight/Obese Adults With Insulin Resistance}, author = {Anonymous}, journal = {The University of Texas Health Science Center at San Antonio}, year = {2023}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings